News|Articles|June 23, 2026
Help Shape the Future of Responsible AI
Author(s)ACTO
Listen
0:00 / 0:00
Responsible AI in Life Sciences needs more than interest. It needs industry input.
Advertisement
Responsible AI is moving from concept to commercial reality in Life Sciences. This short survey invites pharma, biotech, and med device leaders to share how their teams are approaching AI governance, accountability, risk, and value. Your input will help inform the Responsible AI in Life Sciences (RAIL) initiative’s standards framework, industry report, and future guidance for responsible AI adoption.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan
2
Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeutics
3
FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease
4
Educating Patients About GLP-1s: Q&A with Kristen Hartzell, PharmD
5